Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTR-007
- Development stage
- Preclinical
- Lead developer
- OTR Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OTR-007 is an oral small molecule therapeutic candidate currently in the discovery stage of development by OTR Therapeutics. It is being investigated for potential applications in the fields of immunology and inflammation. While OTR Therapeutics is widely recognized for its RePlace GlycosAminoGlycans (RGTA) technology—which utilizes heparan sulfate mimetics to stabilize the microenvironment and promote tissue regeneration—OTR-007 represents a distinct program utilizing a small molecule modality. The specific biological target and precise mechanism of action for OTR-007 have not yet been disclosed by the developer.
Beyond the preview
Go deeper on OTR-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTR-007.